AgingResearch.NewsJoin free

Phase 4Recruiting

Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans

Sponsor
Washington University School of Medicine (Academic or other)
Enrollment
40 planned
Conditions
Healthy Adult Participants; Age 65 and Older; Age 18 to 40; Immunology
Interventions
Trivalent inactivated influenza vaccine; RabAvert
Ages
adults, older adults
Registry
NCT07914673

Full record on ClinicalTrials.gov

From the registry

This study is being done to better understand how the immune system responds to vaccination against influenza and rabies. Researchers want to study how immune responses develop and change over time in the blood and in the lymph nodes that drain the vaccination site, following vaccination with two vaccines licensed by the U.S. Food and Drug Administration (FDA): the seasonal trivalent influenza vaccine (TIV) and the rabies vaccine (RabAvert). By studying these samples, researchers hope to learn how the body produces high-quality, long-lasting antibody and memory immune responses after vaccination. The study will also compare immune responses in younger adults to immune responses in older adults, because prior research suggests that the immune system's ability to respond to vaccination weakens with age.

Primary outcomes

  • Rabies-specific antibody titers at day 29 compared to pre-vaccination baseline.

History

  1. Study completion expected

  2. Primary completion expected

  3. Registered

  4. Started